Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males
- PMID: 19183077
- DOI: 10.1089/apc.2008.0106
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males
Abstract
We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents. The first case, a 16-year-old African American male with an absolute CD4+ cell count of 314 cells/mm(3), presented with an abrupt rise in serum creatinine leading to irreversible renal failure while on TDF-containing highly active antiretroviral therapy (HAART). While the patient had evidence of underlying kidney disease, the timing of his renal failure indicates that TDF played a central role. The second case, a 16-year-old African-American male with an absolute CD4+ cell count of 895 cells/mm3, presented with rickets and hypophosphatemia while receiving TDF-based HAART. To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients. We believe these cases highlight important and potentially irreversible side effects of this agent and emphasize the need for further studies of the renal safety of TDF in pediatric patients.
Similar articles
-
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.AIDS. 2009 Mar 27;23(6):689-96. doi: 10.1097/QAD.0b013e3283262a64. AIDS. 2009. PMID: 19262355
-
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).AIDS Res Hum Retroviruses. 2010 Nov;26(11):1221-7. doi: 10.1089/aid.2009.0261. Epub 2010 Sep 21. AIDS Res Hum Retroviruses. 2010. PMID: 20854202
-
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):301-4. J Acquir Immune Defic Syndr. 2005. PMID: 15735448
-
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.Eur J Clin Pharmacol. 2014 Sep;70(9):1029-40. doi: 10.1007/s00228-014-1712-z. Epub 2014 Jun 25. Eur J Clin Pharmacol. 2014. PMID: 24958564 Review.
-
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.AIDS Patient Care STDS. 2013 Sep;27(9):493-7. doi: 10.1089/apc.2013.0008. Epub 2013 Aug 12. AIDS Patient Care STDS. 2013. PMID: 23937548 Free PMC article. Review.
Cited by
-
Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.Drug Saf. 2016 Mar;39(3):209-18. doi: 10.1007/s40264-015-0371-z. Drug Saf. 2016. PMID: 26692394
-
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.BMC Infect Dis. 2022 Jul 20;22(1):634. doi: 10.1186/s12879-022-07608-8. BMC Infect Dis. 2022. PMID: 35858874 Free PMC article. Clinical Trial.
-
Update on tenofovir toxicity in the kidney.Pediatr Nephrol. 2013 Jul;28(7):1011-23. doi: 10.1007/s00467-012-2269-7. Epub 2012 Aug 10. Pediatr Nephrol. 2013. PMID: 22878694 Review.
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens.Infect Chemother. 2015 Dec;47(4):239-46. doi: 10.3947/ic.2015.47.4.239. Epub 2015 Dec 30. Infect Chemother. 2015. PMID: 26788407 Free PMC article.
-
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.HIV AIDS (Auckl). 2013 Sep 16;5:263-74. doi: 10.2147/HIV.S36311. HIV AIDS (Auckl). 2013. PMID: 24068878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials